Nasdaq:GOSS
Gossamer Bio, Inc.
A clinical-stage biopharma firm utilizing a proprietary platform to develop treatments for severe inflammatory diseases and chronic pain conditions.
Key Metrics
Investment Thesis
Bull Case
The company's proprietary technology platform offers a high-potential pipeline for treating severe inflammatory diseases and chronic pain, areas with substantial unmet medical need. Positive gross profit generation suggests successful licensing deals or commercial partnerships that could provide a stable revenue stream independent of direct product sales. With current cash equivalents at $46.1M, the company has sufficient liquidity to continue advancing its clinical programs and potentially achieve milestone-based profitability in the near term.
Bear Case
Investors should be cautious due to the massive accumulated deficit of $1.27 billion and a net loss of $56.5M, indicating a long path to positive earnings or significant dilution from future equity offerings. The company's lack of capital expenditures and negative operating cash flow highlights its heavy reliance on external funding to sustain operations and clinical trials. Any failure in upcoming clinical trials could result in total write-downs of the asset value, severely impacting the stock price given the current market valuation.
About Gossamer Bio, Inc.
Gossamer Bio is a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics to treat severe inflammatory diseases and chronic pain. The company leverages its unique technology platform to generate revenue through licensing agreements and commercialization partnerships within the specialty pharmaceutical market. Key products are driven by their proprietary drug discovery engine targeting specific biological pathways for unmet medical needs.
Analysis
Management Discussion
While the company generated $114.7M in revenue and posted positive gross profit, it recorded a net loss of $56.5M for the latest period, marking an improvement from previous years but still reflecting the cash-intensive nature of drug development. Operating expenses of $174.6M were significantly higher than gross profit, driven by general and administrative costs and share-based compensation totaling over $20M. Cash flow from operations was negative at $3.5M, offset by $29M in investing cash flows, likely related to strategic asset acquisitions or liquidations given the zero capital expenditures line item.
Industry Overview
The biopharmaceutical industry is characterized by high innovation potential but also extreme financial risk, particularly for companies in the clinical-stage development phase like Gossamer Bio. Success depends on navigating complex regulatory environments and achieving breakthrough results in large-scale clinical trials to gain approval from agencies like the FDA. Companies in this sector often rely on strategic partnerships and licensing deals to share the burden of R&D costs and mitigate financial risk.
Financial Statements
Income Statement
Balance Sheet
Cash Flow
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Revenue | $0 | $0 | $114.7M |
| Cost of Revenue | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $114.7M |
| Operating Expenses | $218.6M | $183.8M | $174.6M |
| Operating Income | $-218.6M | $-183.8M | $-59.9M |
| G&A | $47.6M | $38.5M | $36.1M |
| Stock-Based Comp | $42.6M | $28.5M | $20.6M |
| D&A | $1.8M | $1.6M | $833.0K |
| Depreciation | $1.8M | $1.6M | $800.0K |
| Other OpEx | $171.0M | $145.3M | $138.5M |
| Non-Operating Income | $-10.8M | $4.0M | $4.3M |
| Interest Expense | $13.9M | $13.5M | — |
| Interest Income | — | $2.0M | $1.8M |
| Pre-Tax Income | $-229.4M | $-179.8M | $-55.6M |
| Income Tax | $8.0K | $8.0K | $893.0K |
| Continuing Ops | $-229.4M | $-179.8M | $-56.5M |
| Discontinued Ops | $0 | $0 | $0 |
| Net Income | $-229.4M | $-179.8M | $-56.5M |
| Minority Interest | $0 | $0 | $0 |
| Net to Common | $-229.4M | $-179.8M | $-56.5M |
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Current Assets | $261.9M | $306.5M | $309.9M |
| Cash & Equivalents | $112.0M | $32.1M | $46.1M |
| Marketable Securities | $143.7M | $264.3M | $248.4M |
| Accounts Receivable | — | — | $5.3M |
| Prepaid Expenses | $6.2M | $10.1M | $10.0M |
| Other Current Assets | $0 | $0 | $0 |
| Long-Term Assets | $10.6M | $5.4M | $5.4M |
| PP&E (Net) | $4.0M | $1.6M | $10.0K |
| Operating Leases | $5.9M | $3.1M | $5.1M |
| Other LT Assets | $680.0K | $618.0K | $283.0K |
| Total Assets | $272.4M | $311.9M | $315.3M |
| Current Liabilities | $49.2M | $51.6M | $45.0M |
| Accounts Payable | $1.5M | $5.5M | $2.3M |
| Current Debt | $11.6M | $11.6M | $0 |
| Current Leases | $3.0M | $3.3M | $961.0K |
| Deferred Revenue | — | — | $17.1M |
| Other Current Liab | $12.6M | $4.5M | $9.5M |
| Long-Term Liabilities | $211.1M | $197.5M | $240.8M |
| Long-Term Debt | $12.0M | $814.0K | $0 |
| LT Operating Leases | $3.4M | $144.0K | $4.4M |
| Other LT Liab | $195.7M | $196.6M | $197.5M |
| Total Liabilities | $260.4M | $249.1M | $285.8M |
| Shareholders' Equity | $12.1M | $62.8M | $29.5M |
| Retained Earnings | $-1.03B | $-1.21B | $-1.27B |
| AOCI | $-574.0K | $-350.0K | $1.2M |
| Total L&E | $272.4M | $311.9M | $315.3M |
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Net Income (CFO) | $-229.4M | $-179.8M | $-56.5M |
| Non-Cash Adjustments | $44.9M | $17.0M | $3.0M |
| Working Capital Changes | $-2.6M | $3.6M | $50.1M |
| Cash from Operations | $-187.0M | $-159.2M | $-3.5M |
| Capital Expenditures | $410.0K | $0 | $0 |
| Cash from Investing | $-1.0M | $-111.0M | $29.0M |
| Debt Repayments | $5.8M | $11.6M | $12.6M |
| Cash from Financing | $117.1M | $190.2M | $-11.5M |
| FX Effect | $-517.0K | $110.0K | $-102.0K |
| Net Change in Cash | $-71.5M | $-79.9M | $14.0M |
| Beginning Cash | $183.5M | $112.0M | $32.1M |
| Ending Cash | $112.0M | $32.1M | $46.1M |
Frequently Asked Questions
How does Gossamer Bio, Inc. make money?
Revenue is primarily derived from licensing and commercialization partnerships under the company's innovative drug discovery platform, with recent data indicating significant gross profit generation likely tied to milestone payments or upfront license fees rather than traditional product sales. The financials show substantial deferred revenue, suggesting a business model reliant on long-term partnership agreements and potential future royalty streams.
What are the main risks for GOSS?
The company faces substantial financial risk due to a significant accumulated deficit of over $1.2 billion and recurring net losses, raising concerns about long-term cash runway and the need for future fundraising. Heavy dependence on licensing agreements means revenue volatility could occur if key partnerships fail to deliver expected milestones or commercial success. Clinical trial outcomes remain uncertain, with a high probability of failure for early-stage biotech assets potentially impacting stock valuation significantly.
What is GOSS's competitive advantage?
The company possesses a proprietary technology platform designed specifically for the discovery and development of novel therapeutics for severe inflammatory diseases. Their unique approach to drug discovery offers a differentiated pipeline that addresses significant unmet medical needs in the chronic pain and inflammation markets. Strong balance sheet liquidity provides the capital necessary to advance clinical trials without immediate reliance on external financing, reducing dilution risk for shareholders.
Related Companies
Not financial advice. All content is for informational purposes only. Data may contain errors. Consult a qualified financial advisor before making investment decisions.